New Delhi, Aug. 7 -- Biocon is not rushing to react to proposed US tariffs on generic drugs in its largest market as it sees the move as a negotiation tactic rather than a real threat, executive chairperson Kiran Mazumdar-Shaw told Mint in an interview, noting that tariffs would undermine Washington's efforts to lower healthcare costs. The biopharmaceutical giant, which is among the world's top biosimilar manufacturers, remains in wait-and-watch mode, while exploring US manufacturing partnerships if required, Shaw said.

The company has already expanded manufacturing capabilities in the US and is open to looking at other opportunities, she added. "There are certain products that we are already looking at making in the US. We announced tha...